Intervention research status of traditional Chinese medicine monomers on autoimmune diseases by regulating Th17/Treg axis based on gut microbiota
- VernacularTitle:中药单体基于肠道菌群调节Th17/Treg轴对自身免疫性疾病的干预研究现状
- Author:
Jinyu HUANG
1
;
Zhengwei DONG
1
;
Yongxia WANG
1
Author Information
1. Center of Heart，the First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450003，China
- Publication Type:Journal Article
- Keywords:
monomers of traditional Chinese medicine;
autoimmune diseases;
gut microbiota;
helper T cell 17;
regulatory
- From:
China Pharmacy
2023;34(20):2550-2555
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune diseases（ADs） are diseases in which the body’s immune tolerance is impaired， causing damage to its tissues. The pro-inflammatory helper T cell 17 （Th17） and anti-inflammatory regulatory T cell （Treg） are functionally antagonistic to each other， and the immune imbalance between them and the imbalance of related inflammatory factors are closely related to the occurrence of a variety of ADs. Plenty of evidence has shown that gut microbiota can regulate Th17/Treg differentiation， rebuild immune tolerance and delay the ADs process through regulating cytokine production， transcription factor expression and energy metabolism. This paper reviews the intervention effects of traditional Chinese medicine（TCM） monomers on the common ADs by regulating Th17/Treg differentiation balance based on intestinal flora： ulcerative colitis，rheumatoid arthritis and diabetes mellitus type 1. It is found that its mechanism of action may be to restore the balance of pro-inflammatory factors and anti-inflammatory factors to alleviate intestinal mucosal barrier damage， reduce synovial angiogenesis and improve pancreatic β cell destruction， which provides some ideas for the prevention and treatment of ADs with integrated traditional Chinese and western medicine.
